Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.

In conclusion, bexarotene markedly alleviates the neurological deficits, improves the histological outcome, and inhibits cell apoptosis in mice after t-MCAO. This effect is mediated, at least in part, by up-regulation of APOE. Thus, bexarotene may be a candidate drug for the treatment of cerebral ischemia patients.
PMID: 31680194 [PubMed - as supplied by publisher]

Source: Neurochemical Research - November 2, 2019 Category: Neuroscience Authors: Liu H, Liu S, Tian X, Wang Q, Rao J, Wang Y, Xiang F, Zheng H, Xu L, Dong Z Tags: Neurochem Res Source Type: research